Table 3.
The association between clinicopathologic characteristics and Id 1-3 expression and MVD-VEGF and MVD-CD34
| Id-1 |
Id-2 |
Id-3 |
MVD-VEGF |
MVD-CD34 |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age | ≤497 | >497 | ≤578 | >578 | ≤590 | >590 | ≤55 | >55 | ≤24.3 | >24.3 |
| ≤67 yr | 18 (52.9%) | 17 (45.9%) | 18 (50%) | 18 (45%) | 15 (44.1%) | 19 (55.9%) | 20 (55.9%) | 16 (45.7%) | 16 (40.4%) | 24 (61.5%) |
| >67 yr | 16 (47.1%) | 20 (54.1%) | 18 (50%) | 22 (55.5%) | 14 (37.8%) | 23 (62.2%) | 15 (42.9%) | 19 (54.3%) | 20 (55.6%) | 15 (38.5%) |
| Gender | ||||||||||
| Women | 13 (46.4%) | 22 (51.2%) | 12 (33.3%) | 24 (66.7%) | 19 (55.9%) | 18 (46.2%) | 15 (44.1%) | 19 (55.9%) | 13 (32.5%) | 27 (67.5%) |
| Men | 15 (53.6%) | 21 (48.8%) | 18 (45.0%) | 22 (55%) | 14 (37.8%) | 23 (62.2%) | 14 (37.8%) | 23 (62.2%) | 16 (45.7%) | 19 (54.3%) |
| T stage | ||||||||||
| T1 | 7 (20.6%) | 5 (14.3%) | 8 (23.9%)* | 4 (10.3%) | 7 (21.2%) | 4 (11.1%) | 5 (13.9%) | 7 (21.9%) | 6 (15.8%) | 6 (17.1%) |
| T2 | 24 (70.6%) | 24 (68.6%) | 24 (68.6%) | 29 (74.4%) | 23 (69.7% | 26 (72.2%) | 26 (72.2%) | 21 (65.6%) | 30 (78.9%) | 22 (62.9%) |
| T3 | 3 (8.8%) | 3 (8.6%) | 3 (8.6%0) | 3 (7.7%) | 2 (6.1%) | 4 (11.1%) | 4 (11.1%) | 2 (6.3%) | 2 (5.3%) | 4 (11.4%) |
| T4 | 0 (0.0%) | 3 (8.6%) | 0 (0%) | 3 (7.7%) | 1 (3.0) | 2 (5.6%) | 1 (2.8%) | 2 (6.3%) | 0 (0.0%) | 3 (8.6%) |
| N stage | ||||||||||
| N0 | 20 (60.6%) | 21 (67.7%) | 20 (58.8%) | 24 (70.6%) | 17 (56.7%) | 25 (75.8% | 22 (64.7%) | 19 (67.9%) | 24 (68.6%) | 20 (62.5%) |
| N1 | 10 (30.3%) | 7 (22.6%) | 11 (32.4% | 7 (20.6% | 11 (36.7% | 5 (15.2%) | 9 (26.5) | 7 (25%) | 7 (20.0%) | 10 (31.3%) |
| N2 | 3 (9.1%) | 3 (9.7%) | 3 (8.8%) | 3 (8.8%) | 2 (6.7%) | 3 (9.1%) | 3 (60.0%) | 2 (7.1%) | 4 (11.4%) | 2 (6.3%) |
| Stage | ||||||||||
| Ia | 7 (17.9%) | 2 (5.1%) | 7 (17.1%) | 2 (4.8%) | 6 (15.4%) | 2 (5.1%) | 4 (10.3%) | 5 (12.8%) | 5 (12.2%) | 4 (9.5%) |
| Ib | 16 (41%) | 19 (48.7%) | 16 (39.0%) | 23 (54.8%) | 13 (33.3%) | 24 (61.5% | 19 (48.7%) | 17 (43.6%) | 26 (63.4%) ‡ | 13 (31.0%) |
| IIa | 0 (0%) | 1 (2.6%) | 1 (2.4%) | 0 (0%) | 0 (10.0%) | 1 (2.6%) | 0 (0.0%) | 1 (2.6%) | 0 (0.0%) | 1 (2.4%) |
| IIb | 9 (23.1%) | 10 (25.6% | 9 (22.0%) | 11 (26.2%) | 13 (33%)† | 6 (15.4%)† | 10 (25.6%) | 8 (20.5%) | 6 (14.6%) | 13 (31.0%) |
| IIIa | 4 (10.3%) | 3 (7.7%) | 4 (9.8%) | 3 (7.1%) | 2 (5.1%) | 4 (10.3%) | 3 (7.7%) | 3 (7.7%) | 4 (9.8%) | 3 (7.1%) |
| IIIb | 0 (0%) | 1 (2.6%) | 0 (0%) | 1 (2.4%) | 0 (0.0%) | 1 (2.6%) | 1 (2.6%) | 0 (0%) | 0 (0.0%) | 1 (2.4%) |
| Lymph | ||||||||||
| N = 0 | 26 (89.7%) | 24 (88.9%) | 26 (89.7%) | 29 (90.6%) | 24 (92.3%) | 28 (90.3%) | 30 (90.9%) | 20 (90.9%) | 26 (86.7%) | 28 (93.3%) |
| N = 1 | 1 (3.4%) | 1 (3.7%) | 1 (3.4%) | 1 (3.1%) | 1 (3.8%) | 1 (3.2%) | 1 (3.0%) | 1 (4.5%) | 1 (3.3%) | 1 (3.3%) |
| N = 2 | 0 (0.0%) | 1 (3.7%) | 0 (0.0%) | 1 (3.1%) | 1 (3.8%) | 0 (0.0%) | 1 (3.0%) | 0 (0.0%) | 1 (3.3%) | 0 (0.0%) |
| N = 3 | 2 (6.9%) | 1 (3.7%) | 2 (6.9%) | 1 (3.1%) | 0 (0.0%) | 2 (6.5%) | 1 (3.0%) | 1 (4.5%) | 2 (6.7%) | 1 (3.3%) |
MVD: microvessel density.
Distribution of the morphometric results of Id1-3 histoscores, MVD-CD34 and MVD-VEGF tumor staining according to patients’ clinicopathologic features. Chi-square test was used to associate clinical and morphological variables; P value = 0.05.
*
Linear-by-linear association (R) = 3.3, P value = 0.05.
†
Likelihood ratio (R) = 14.42, P value = 0.02.
‡
Likelihood ratio (R) = 19.77, P value = 0.003.